Skip to main content
. 2021 Aug;13(8):4668–4677. doi: 10.21037/jtd-21-150

Figure 1.

Figure 1

Kaplan-Meier estimate of OS. (A) Kaplan-Meier estimate of OS subgroups by duration of denosumab and ICI overlap (11.5 vs. 3.6 months, P=0.0005). (B) Kaplan-Meier estimate of OS subgroups by brain metastases (7.7 vs. 3.6 months, P=0.16). (C) Kaplan-Meier estimate of OS subgroups by line of therapy i.e., first line vs. second line (8.9 vs. 3.9 months, P=0.03). (D) Kaplan-Meier estimate of OS subgroups by skeletal metastases (7.7 vs. 4 months, P=0.2). ICI, immune checkpoint inhibitors.